TITLE

The Next Cancer Bestseller?

AUTHOR(S)
Langreth, Robert
PUB. DATE
May 2009
SOURCE
Forbes Asia;5/11/2009, Vol. 5 Issue 8, p48
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information on Afinitor, kidney cancer drug from Novartis AG. Afinitor was approved in March 2009 for patients with advanced kidney cancer who failed other treatments. Novartis plans to test Afinitor simultaneously on five other tumor types, including breast, stomach, and neuroendocrine tumor. A trial on 416-patient led by oncologist Robert Motzer found that Afinitor delayed disease progression in patients with kidney cancer by three months.
ACCESSION #
41227143

 

Related Articles

  • Bristol-Myers: kidney drug win. Investor's Business Daily // Investors Business Daily;7/21/2015, pA02 

    The article reports on the approval received by Opdivo for treatment of kidney cancer with everolimus, by pharmaceutical company, Novartis AG.

  • Opinion: Novartis: Menveo is ready to be submitted.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p27 

    The article reports on the proven efficacy of meningcoccal vaccine developed by Novartis AG called Menveo. The vaccine is effective in infants and older persons based on trials it had undergone wherein it has been shown to improve on the recent gold standard treatment in certain age groups. The...

  • Results Update.  // PharmaWatch: Biotechnology;Dec2005, Vol. 4 Issue 12, p8 

    The article presents the results of the tests conducted by various companies on the effects of various drugs. Results showed that the addition of the Genentech Inc. drug Herceptin in chemotherapy led to reduction in recurrence of breast cancer in women. Genentech Inc. has abandoned a phase II...

  • Denosumab in Oncology: Two Down, Whopper to Go. Morrison, Trista // BioWorld Today;8/5/2009, Vol. 20 Issue 149, p3 

    The article reports on the achievement of the primary endpoint by Amgen Incorporated's denosumab in its second Phase III oncology trial. Earlier, the drug showed superiority to Novartis AG's Zometa or zoledronic acid in advanced breast cancer patients with bone metastases. The delay of...

  • Breast Cancer Update.  // PharmaWatch: Cancer;May2006, Vol. 5 Issue 5, p14 

    The article reports on developments related to breast cancer drug manufacturing. GlaxoSmithKline PLC has ended its phase III clinical trial of Tykerb after the drug achieved statistical significance in helping women with advanced breast cancer. Femara of Novartis AG was designed to improve...

  • Bisphosphonate Warning.  // Townsend Letter for Doctors & Patients;Apr2005, Issue 261, p18 

    Provides evidence on the effectiveness and side-effects of bisphosphonate. Details about a health warning released by Novartis concerning two of its bisphosphonate drugs, Zometa (zoledronic acid) and Aredia (pamidronate disodium) which are both indicated for cancer-induced hypercalcemia,...

  • Anastrozole 'provides protection'.  // British Journal of Hospital Medicine (17508460);Feb2008, Vol. 69 Issue 2, p73 

    The article focuses on the 100-month Arimidex, Tamoxifen, Alone, or in Combination trial data, which are designed to see the treatment advantages of anastrozole over tamoxifen that will be seen in postmenopausal women diagnosed with early stage disease in Great Britain. The data showed...

  • Opinion: GlaxoSmithKline: Tykerb steps up challenge to Herceptin.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p6 

    The article focuses on a second Phase III clinical trial set by GlaxoSmithKline (GSK) which aims to compare Tykerb and Herceptin as treatment for breast cancer. Tykerb will be tested against Herceptin as a neoadjuvant therapy in breast cancer patients. GSK hopes that Tykerb will advance...

  • Amgen's denosumab increases bone density in breast cancer patients.  // PharmaWatch: Biotechnology;Feb2008, Vol. 7 Issue 2, p8 

    The article focuses on the positive results of the first Phase III pivotal study to complete the denosumab oncology development program made by Amgen Inc. in the U.S. The results from the Phase III HALT breast cancer135 study revealed that denosumab increased bone density worsened by aromatase...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics